Yintao Li

Dr. Yintao Li

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 July 2025 in Journal of Hematology & Oncology
Verified
Journal Article
Open access
PDF file
JTJinxin Tang
Jinxin Tang
YZYan Zhuang
Yan Zhuang
YZYibo Zhang
Yibo Zhang
HHHongkun Hu
Hongkun Hu
HWHua Wang
Hua Wang
Chao TuChao Tu
Chao Tu
Necroptosis represents a distinct form of programmed cell death that exhibits characteristics of both necrosis and apoptosis. Due to its potential to activate anti-cancer immune responses, utilizing necroptosis to enhance immune activity within the tumor microenvironment has garnered significant attention. However, effectively regulating necroptosis in cancer remains a formidable challenge. Epigenetic, post-transcriptional and post-translational modifications are three primary mechanisms that alter molecular expression patterns without changing DNA sequence, playing crucial roles in cancer progression. While these modifications have been shown to significantly influence cancer development, their specific roles in regulating necroptosis in cancer have not been systematically elucidated. This review explores the role and mechanism of epigenetic, post-transcriptional and post-translational modification in the regulation of necroptosis in cancer, identifying potential regulatory targets and their therapeutic implications, thereby providing systematic theoretical support for necroptosis as an emerging target for cancer therapy.

1 January 2018 in Journal of Cancer
Verified
Journal Article
Open access
YXYali Xu
Yali Xu
XLXiaoyan Lin
Xiaoyan Lin
JXJiawen Xu
Jiawen Xu
HJHaiyan Jing
Haiyan Jing
YQYejun Qin
Yejun Qin
YLYintao Li
Yintao Li
Sulfotransferase family 1E member 1 (SULT1E1) is known to catalyze sulfoconjugation and play a crucial role in the deactivation of estrogen homeostasis, which is involved in tumorigenesis and the progression of breast and endometrial cancers. Our previous study has shown that the protein levels of SULT1E1 were decreased in breast cancer; however, the underlying mechanism is still poorly understood. In this study, we explored the functional and molecular mechanisms by which SULT1E1 influenced breast cancer. Here, we identified that overexpression of SULT1E1 inhibited breast cancer cell growth through inducing apoptosis and arresting cell cycle progression. Furthermore, enforced expression of SULT1E1 suppressed tumor cell migration and invasion. Moreover, we found that the activation of PPARγ was required for SULT1E1-mediated downregulation of C-myc, Cyclin D1, MMP-2 and MMP-9 as well as for cell apoptosis, migration and invasion. In addition, the overexpression of SULT1E1 significantly inhibited tumor growth in vivo. Taken together, our findings indicated that SULT1E1 performed its tumor suppressor characteristics by activating PPARγ, which provided a novel target for patients with breast cancer.

17 March 2025 in Experimental Hematology & Oncology
Verified
Journal Article
Open access
PDF file
YLYing Li
Ying Li
JZJunfeng Zhao
Junfeng Zhao
YLYintao Li
Yintao Li
The development of Kirsten rat sarcoma viral oncogene homologue (KRAS) targeted therapies has been the focus of cancer treatment. The most common mutant subtypes of KRAS driver genes are G12C, G12V, and G12D, and are associated with poor prognosis. Up to now, inhibitors specifically targeting KRASG12D mutant proteins are all in the pre-clinical/early clinical research stage, and there is still a lack of effective clinical targeting strategies. In their recently published article, Zhou et al. developed a high-affinity, selective, long-acting, non-covalent KRASG12D-specific inhibitor and, further combined with the proteasome inhibitor carfilzomib, found that this protocol can achieve the purpose of killing mutant cell lines and inhibiting tumor growth in vitro and in vivo. Here, we aim to describe a potential novel therapy for patients with KRASG12D mutations and present the first KRASG12D-specific inhibitor to be proven as clinically effective. Different mutations of KRAS gene and mechanisms of KRAS drug resistance were also discussed.

1 December 2023 in Cancer Pathogenesis and Therapy
Verified
Journal Article
Open access
YLYing Li
Ying Li
JZJunfeng Zhao
Junfeng Zhao
YWYue Wang
Yue Wang
YXYali Xu
Yali Xu
RLRuyue Li
Ruyue Li
YLYintao Li
Yintao Li
Immune checkpoint inhibitors (ICIs), a novel anti-tumor therapeutic modality, are monoclonal antibodies targeting certain immune checkpoints (ICs) that reactivate T cells to achieve anti-tumor immunity by targeting, binding, and blocking ICs. Targeted inhibitory antibodies against the ICs cytotoxic T-lymphocyte antigen and programmed death receptor-1 have demonstrated efficacy and durable anti-tumor activity in patients with cancer. ICs may prevent autoimmune reactions. However, ICIs may disrupt ICs properties and trigger autoimmune-related adverse reactions involving various organ systems including the cardiovascular, pulmonary, gastrointestinal, renal, musculoskeletal, dermal, and endocrine systems. Approximately 10% of patients with damage to target organs such as the thyroid, pituitary, pancreas, and adrenal glands develop endocrine system immune-related adverse events (irAEs) such as thyroid dysfunction, pituitary gland inflammation, diabetes mellitus, and primary adrenal insufficiency. However, the symptoms of immunotherapy-associated endocrine system irAEs may be nonspecific and similar to those of other treatment-related adverse reactions, and failure to recognize them early may lead to death. Timely detection and treatment of immunotherapy-associated endocrine irAEs is essential to improve the efficacy of immunotherapy, prognosis, and the quality of life of patients. This study aimed to review the mechanisms by which ICIs cause endocrine irAEs providing guidance for the development of appropriate management protocols. Here, we discuss (1) the biological mechanisms of ICs in tumorigenesis and progression, focusing on cytotoxic T-lymphocyte antigen and programmed cell death-1/programmed cell death-ligand 1; and (2) the epidemiology, clinical symptoms, diagnosis, and treatment of four immunotherapy-related endocrine complications.

1 October 2024 in Translational Lung Cancer Research
Verified
Journal Article
Open access
PDF file
YLYing Li
Ying Li
JZJunfeng Zhao
Junfeng Zhao
RLRuyue Li
Ruyue Li
XYXiujing Yao
Xiujing Yao
XDXue Dong
Xue Dong
YLYintao Li
Yintao Li
Background: Patients with stage IA lung adenocarcinoma (ADC) with an micropapillary (MIP) component are at a higher risk of recurrence after radical surgical resection; however, adding adjuvant chemotherapy (ACT) to their postoperative course remains controversial. This study determined the predictive factors that influence the prognosis of these patients and identified those at high risk of recurrence. Methods: Between January 2012 and December 2018, 254 eligible patients with stage IA lung ADC with an MIP component were categorized into training (n=169) and validation (n=85) cohorts. Clinicopathological and radiomics features were included in univariate and multivariate analyses, and statistically significant predictors were used to develop the nomogram. Area under the curve (AUC) of receiver operating characteristic (ROC) curves, calibration curves, and decision curve analysis (DCA) were used to validate the model. The calculated risk scores for each patient were risk-stratified using the X-tile procedure, and survival analyses were performed among the different risk subgroups. Results: T1c stage, MIP ≥1%, spread through air space (STAS), carcinoembryonic antigen (CEA) >5 µg/L, and radiomics features were independent predictors of overall survival (OS) and disease-free survival (DFS) in patients with lung ADC with an MIP component at stage IA. Incorporating this into the nomogram, the AUCs of the nomogram predicting 3-, 5-, and 7-year OS and DFS were 0.910, 0.914, and 0.904 and 0.868, 0.838, and 0.848, respectively, in the training cohort and 0.879, 0.895, and 0.899 and 0.817, 0.805, and 0.811, respectively, in the validation cohort, showing good differentiation. The OS and DFS survival analyses among different risk subgroups showed that the nomogram could well distinguish between low- and high-risk groups. Conclusions: We developed and validated a nomogram based on clinicopathological factors and radiomics features, which can be used as a powerful tool for predicting postoperative recurrence and survival in patients with stage IA lung ADC containing an MIP component.

14 March 2025 in Discover Oncology
Verified
Journal Article
Open access
PDF file
RLRuyue Li
Ruyue Li
HZHuanle Zhang
Huanle Zhang
YLYing Li
Ying Li
XYXiujing Yao
Xiujing Yao
XDXue Dong
Xue Dong
YLYintao Li
Yintao Li
Background Patients with advanced pulmonary large-cell neuroendocrine carcinoma (LCNEC) have a progressive clinical course and poor prognosis, and effective treatment options remain limited. This study assessed the efficacy and safety of immunotherapy plus chemotherapy for advanced LCNEC. Methods We retrospectively collected medical records of patients with advanced LCNEC who attended Shandong Cancer Hospital from January 2018 to December 2022. Patients were divided into two groups based on their previous treatment regimen: immunotherapy plus chemotherapy and chemotherapy alone. Kaplan–Meier survival curves and Cox regression models were used to evaluate the clinical efficacy of different treatment regimens. Results The median follow-up was 29.33 months (95% confidence interval [CI]: 24.04–not reached). The median overall survival (OS) was 15.01 months (95% CI: 11.99–26.31) and 7.19 months (95% CI: 5.15–10.57) in the immunotherapy plus chemotherapy and chemotherapy groups, respectively (P = 0.001). Following propensity score matching, the median OS was 17.41 months (95% CI: 11.99–29.20) and 5.88 months (95% CI: 4.50–11.53) in the immunotherapy plus chemotherapy and chemotherapy groups, respectively. The median progression-free survival was 6.70 months (95% CI: 5.48–13.27) and 3.12 months (95% CI: 2.52–4.20) in the immunotherapy plus chemotherapy and chemotherapy groups, respectively. We also found that increasing age may contribute to poorer prognosis in patients with advanced LCNEC (P < 0.05). Conclusions Immunotherapy plus chemotherapy significantly improved OS compared with chemotherapy in LCNEC, with a tolerable safety profile without life-threatening adverse events. Immunotherapy plus chemotherapy may be an effective treatment option for patients with advanced LCNEC.